References
- Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012;45:7–35
- Ljubojevic S, Lipozenčić J. Autoimmune bullous diseases associations. Clin Dermatol. 2012;30:17–33
- Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–8
- Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2011;67:617–22
- Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132:203–12
- Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61–73
- Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies. Clin Dermatol. 2010;28:337–43
- Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30:78–83
- Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolatemofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447–54
- Mimouni D, Nousari CH, Cummins D, et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49:1059–62
- Toth GG, Jonkman MF. Therapy of pemphigus. Clin Dermatol. 2001;19:761–7
- Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30:84–94
- Peters DH, Fitton A, Plosker GL, et al. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46:746–94
- Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404–30
- Bhang DH, Choi US, Jung YC, et al. Topical 0.03% tacrolimus for treatment of pemphigus erythematosus in a Korea Jindo dog. J Vet Med Sci. 2008;70:415–7
- Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol. 2006;45:1379
- Gach JE, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol. 2004;29:271–2
- Hodgson TA, Malik F, Hegarty AM, Porter SR. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol. 2003;13:142–4
- Busing V, Kern JS, Bruchner-Tuderman L, Hofmann SC. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus. Dermatology. 2010;221:122–6
- Takae Y, Takeji N, Amagai M. Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. Exp Dermatol. 2009;18:252–60
- Bolognia JL, Jorizzo JL, Rapini RP. Dermatology, vol 2, 2nd ed. St. Louis: Mosby, 2008:2010
- Amagai M, Ikeda SH, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603
- Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–6
- Grando SA. Development of concepts of etiology, pathogenesisand treatment of pemphigus vulgaris based on the hypothesis of atavistic origin of the disease. Med Hypotheses. 1991;36:43–52
- Strowad LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol. 2011;64:490–4
- Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment ofpemphigus vulgaris: a long-term follow-up. J Am Acad Dermatol. 1987;16:527–33
- Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment ofpemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003;49:276–80
- Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132:1435–9
- Frydman AS, Fairley JA. New and innovative interventions in the management of pemphigus. G Ital Dermatol Venereol. 2011;146:211–24
- Madan V, Griffiths CE. Systemic cyclosporine and tacrolimus in dermatology. Dermatol Ther. 2007;20:239–50
- Suresh L, Calixto LEM, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist. 2006;26:66–70
- Hofmann SC, Kautz O, Hertel M, et al. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges. 2009;7:227–33
- Bolognia JL, Jorizzo JL, Rapini RP. Dermatology, vol. 2, 2nd ed. St. Louis: Mosby, 2008. p 2018